The group's principal activity is research, development and commercialization of patented technologies in the field of transplantation therapy for patients with insulin-dependent diabetes. The group has licensed several technologies from duke university medical center developed over the last decade for the isolation, culture, storage and encapsulation (microencapsulation) of insulin-producing islet cells from porcine sources. These methods are among advances in the field of transplantation that may enable diabetic patients to become free from insulin injections.
